Wikipedia

Lyda Osorio

Lyda Elena Osorio Amaya is a Colombian physician, epidemiologist and infectious disease specialist.[1] She is an associate professor at the Universidad del Valle, and a researcher at the Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM) in Cali, Valle del Cauca.[1] Osorio's research has focused mainly on vector-borne diseases like malaria, leishmaniasis, Zika and dengue fever.[2] She has also played a role in Colombia's response against COVID-19.[3]

Lyda Osorio
NationalityColombian
Alma materUniversidad de Caldas (MD), London School of Hygiene and Tropical Medicine (PhD)
Scientific career
FieldsEpidemiology, Infectious disease, Vector-borne disease
InstitutionsUniversidad del Valle, CIDEIM
Thesis Effects of mobility on the transmission of malaria in an urban area in Colombia
Doctoral advisorProf. David Bradley

Education

edit

Osorio studied medicine at the Universidad de Caldas.[1] She then went on to do her 'mandatory social service' at CIDEIM[4] for the final part of her medical degree. Osorio was awarded a scholarship from Colciencias (Colombian government) to pursue a PhD in Epidemiology at the London School of Hygiene and Tropical Medicine.[2] She graduated in 2003, with a doctoral thesis on the effects of human movement on the transmission of malaria in the Colombian city of Quibdó, which is endemic for Plasmodium falciparum and P. vivax.[5][6][7]

Career

edit

Osorio became an associate professor at the School of Public Health of the Universidad del Valle (UVAL) in 2007.[8][1] Between 2014 and 2016, Osorio acted as the director of postgraduate programmes, and in 2018 she became the coordinator of the MSc epidemiology program, at the same University.[8] She conducts research at the Epidemiology and Population Health group at UVAL,[9] and is an associated researcher with CIDEIM.[1][10]

In general her research has focused on the epidemiology, diagnosis and treatment of vector-borne diseases.[2][11] In 2013, Osorio applied for and won a WHO/TDR fellowship to work at GSK's Diseases of the Developing World programme as a postdoctoral fellow.[2] During her year at GSK she worked on a trial evaluating tafenoquine against P. vivax malaria, and on clinical data from a trial studying G6PD deficiency.[2][12] Osorio is a Data Access Committee member of the Worldwide Antimalarial Resistance Network (WWARN).[13] As part of the WWARN's gametocyte study group, she co-authored a meta-analysis of individual patient data to look at the effects of artemisinin combination therapy in gametocyte carriage.[14]

In 2016, Osorio co-led a multi-center case-control study called Neurovirus Emerging in the Americas Study (NEAS), sponsored by Johns Hopkins University, which aimed to characterize the development of neurological symptoms after exposure to dengue, chikungunya and Zika.[15][16] Results from this clinical trial supported the suspected development Guillain–Barré syndrome as a consequence of infection with the Zika virus.[17] Osorio's further work in Zika has included the evaluation of personal protection measures by pregnant women and women of reproductive age in Colombia against the Aedes mosquito vector.[18] She has also worked with dengue diagnosis in Colombia,[19][20][21] and participated in clinical trials evaluating the use of meglumine antimoniate versus miltefosine for the treatment of cutaneous leishmaniasis in adults and children.[22][23]

Work during the COVID-19 pandemic

edit

Osorio has also played a role in Colombia's response against COVID-19.[4] She was designated by the mayor of Cali as the "city's epidemiologist" to help the local Health Department's planning of adequate measures against the pandemic.[3] Osorio is one of several scientists communicating with the Colombian government about strategies to control the spread of the new coronavirus,[24] including a request to support universities working on diagnosis and research.[25]

Other appointments and activities

edit
  • Osorio is a member of the ZikaPLAN Consortium, a network of researchers focused on Zika and other emerging infectious diseases[26][27]
  • Member of the Pan American Health Organization Malaria Technical Advisory Group.[28]
  • Data Access Committee member for the Infectious Diseases Data Observatory (IDDO).[29]
  • Editorial advisory board member for BMJ Global Health.[30]

Awards and recognitions

edit

In December 2020, Osorio received the "Order ‘Confederate Cities’ in the rank of Commander Cross" on Pan American Doctor's day from the governor of Cali (Colombia) for her research and leadership during the COVID-19 pandemic in her country.[31]

For International Women's Day in 2021, Osorio was listed as one of the 15 influential women in science around the world selected by the World Health Organization; Osorio was featured for her work against infectious diseases, and her leadership during the COVID-19 pandemic in Colombia.[32][4]

edit

References

edit
  1. ^ a b c d e "Escuela de Salud Pública - Lyda Elena Osorio Amaya". Universidad del Valle (Colombia) (in Spanish). Retrieved 6 April 2021.
  2. ^ a b c d e "TDR | Dr Lyda Osorio, Colombia". WHO. Retrieved 2021-04-06.
  3. ^ a b "Intervención interdisciplinaria desde la Salud Pública". Universidad del Valle (in Spanish). Retrieved 2021-04-07.
  4. ^ a b c Women in science: a storytelling showcase. Geneva: World Health Organization. 2021. pp. 40–41. hdl:10665/339981. ISBN 978-92-4-002189-1.
  5. ^ Osorio-Amaya LE (2003). Effects of mobility on the transmission of malaria in an urban area in Colombia (Thesis). London School of Hygiene and Tropical Medicine (University of London).
  6. ^ Osorio L, Todd J, Bradley DJ (October 2004). "Travel histories as risk factors in the analysis of urban malaria in Colombia" (PDF). The American Journal of Tropical Medicine and Hygiene. 71 (4): 380–6. doi:10.4269/ajtmh.2004.71.380. PMID 15516630. S2CID 39709766.
  7. ^ Osorio L, Todd J, Bradley D (March 2004). "[Absence of asymptomatic malaria in schoolchildren of Quibdó, Chocó]". Biomedica: Revista del Instituto Nacional de Salud (in Spanish). 24 (1): 13–9. PMID 15239597.
  8. ^ a b "TDR Bio - Dr Lyda Osorio - Amaya". profiles.tdr-global.net. Retrieved 2021-04-06.
  9. ^ "Facultad de Salud". Universidad del Valle. 2019. Retrieved 7 April 2021.
  10. ^ "CvLAC - RG". scienti.minciencias.gov.co. Retrieved 2021-04-08.
  11. ^ Osorio L, Garcia JA, Parra LG, Garcia V, Torres L, Degroote S, Ridde V (September 2018). "A scoping review on the field validation and implementation of rapid diagnostic tests for vector-borne and other infectious diseases of poverty in urban areas". Infectious Diseases of Poverty. 7 (1): 87. doi:10.1186/s40249-018-0474-8. PMC 6120097. PMID 30173662.
  12. ^ Osorio L. "What academics can learn from pharmaceutical clinical research: experiences from the WHO/TDR Fellowship" (PDF). TGHN (in Spanish). Retrieved 7 April 2021.
  13. ^ "Dr Lyda Osorio". Worldwide Antimalarial Resistance Network. 2017-04-11. Retrieved 2021-04-07.
  14. ^ WWARN Gametocyte Study Group (May 2016). "Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data". BMC Medicine. 14 (1): 79. doi:10.1186/s12916-016-0621-7. PMC 4879753. PMID 27221542.
  15. ^ "Clinical Trial on Encephalitis - Clinical Trials Registry - ICH GCP". ichgcp.net. Retrieved 2021-04-07.
  16. ^ Universidad Cooperativa de Colombia. "Noticias UCC". www.ucc.edu.co (in European Spanish). Retrieved 2021-04-07.
  17. ^ Parra B, Lizarazo J, Jiménez-Arango JA, Zea-Vera AF, González-Manrique G, Vargas J, et al. (October 2016). "Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia". The New England Journal of Medicine. 375 (16): 1513–1523. doi:10.1056/NEJMoa1605564. PMID 27705091.
  18. ^ Mendoza C, Jaramillo GI, Ant TH, Power GM, Jones RT, Quintero J, et al. (January 2020). "An investigation into the knowledge, perceptions and role of personal protective technologies in Zika prevention in Colombia". PLOS Neglected Tropical Diseases. 14 (1): e0007970. doi:10.1371/journal.pntd.0007970. PMC 7010294. PMID 31961867.
  19. ^ Caicedo-Borrero DM, Tovar JR, Méndez A, Parra B, Bonelo A, Celis J, et al. (June 2020). "Development and Performance of Dengue Diagnostic Clinical Algorithms in Colombia". The American Journal of Tropical Medicine and Hygiene. 102 (6): 1226–1236. doi:10.4269/ajtmh.19-0722. PMC 7253082. PMID 32342839.
  20. ^ Tello-Cajiao ME, Osorio L (September 2019). "Impact of Dengue Rapid Diagnostic Tests on the Prescription of Antibiotics and Anti-Inflammatory Drugs by Physicians in an Endemic Area in Colombia". The American Journal of Tropical Medicine and Hygiene. 101 (3): 696–704. doi:10.4269/ajtmh.19-0222. PMC 6726934. PMID 31333163.
  21. ^ Osorio L, Uribe M, Ardila GI, Orejuela Y, Velasco M, Bonelo A, Parra B (June 2015). "The use of rapid dengue diagnostic tests in a routine clinical setting in a dengue-endemic area of Colombia". Memórias do Instituto Oswaldo Cruz. 110 (4): 510–6. doi:10.1590/0074-02760140359. PMC 4501415. PMID 25993399.
  22. ^ Castro MD, Cossio A, Velasco C, Osorio L (April 2017). "Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study". PLOS Neglected Tropical Diseases. 11 (4): e0005515. doi:10.1371/journal.pntd.0005515. PMC 5393627. PMID 28379954.
  23. ^ Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, et al. (February 2012). "Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children". The Journal of Infectious Diseases. 205 (4): 684–92. doi:10.1093/infdis/jir816. PMC 3266136. PMID 22238470.
  24. ^ "Variaciones territoriales de la curva Covid – 19 en Colombia: De la eco-epidemiologia a la antropología". MinCiencias Colombia (in Spanish). 2020. Retrieved 7 April 2021.
  25. ^ Varela PW. "Científicos reunidos con senadores piden apoyar a universidades con equipos y personal para aumentar muestras de Covid-19". Senado de la República de Colombia (in European Spanish). Retrieved 2021-04-08.
  26. ^ "Consortium Members". ZikaPLAN. Retrieved 6 April 2021.
  27. ^ Wilder-Smith A, Preet R, Brickley EB, Ximenes RA, Miranda-Filho DB, Turchi Martelli CM, et al. (2019-01-01). "ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas". Global Health Action. 12 (1): 1666566. doi:10.1080/16549716.2019.1666566. PMC 6818126. PMID 31640505.
  28. ^ "PAHO/WHO | Malaria Technical Advisory Group - Current Members". Pan American Health Organization / World Health Organization. 2019-05-25. Retrieved 2021-04-06.
  29. ^ "Dr Lyda Osorio | Infectious Diseases Data Observatory". www.iddo.org. Retrieved 2021-04-13.
  30. ^ "Editorial Board". BMJ Global Health. Retrieved 2021-04-06.
  31. ^ Gobernación del Valle del Cauca. "Por su trabajo investigativo y aporte a la salud para contrarrestar el Coronavirus, la Gobernación condecoró a cuatro médicos de la región". www.valledelcauca.gov.co (in Spanish). Retrieved 2021-04-07.
  32. ^ "Women scientists capture public attention as COVID-19 rages across the world". www.who.int. Retrieved 2021-04-06.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lyda_Osorio&oldid=1184200580"